BioRestorative Secures FDA Phase 3 Alignment, Completes 99-Patient Phase 2 Trial and Raises $5 Million
BioRestorative Therapies completed enrollment of 99 patients in its Phase 2 BRTX-100 trial for chronic lumbar disc disease across 15 U.S. sites and secured FDA alignment on its Phase 3 design. It raised $5 million through a public offering, expanded BioCosmeceutical commercialization, and received Australian patent allowance for its ThermoStem® metabolic platform.
1. Phase 2 Trial Completion and Phase 3 Alignment
BioRestorative enrolled 99 patients across 15 U.S. sites in its fully powered, randomized, double-blind, sham-controlled Phase 2 trial of BRTX-100 for chronic lumbar disc disease. A positive FDA Type B meeting confirmed alignment on Phase 3 design, endpoints, dosing and powering assumptions with no safety concerns, enabling a Phase 3 IND amendment targeted in the second half of 2026.
2. Capital Raise and Commercial Strategy
The company strengthened its balance sheet with a $5 million public offering to extend its operational runway and fund development. It is accelerating its BioCosmeceutical platform under new commercial leadership to generate non-dilutive revenue via global distribution, enterprise clinical adoption and direct-to-consumer channels.
3. ThermoStem® Patent and Pipeline Optionality
BioRestorative received patent allowance in Australia for its ThermoStem® brown adipose-derived stem cell aggregates, reinforcing protection for its off-the-shelf metabolic platform. While BRTX-100 remains the primary value driver, ThermoStem® offers strategic optionality in the obesity and metabolic disorder market.